Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company reports developments in lens-based refractive surgery through its EVO family of Implantable Collamer® Lenses, including EVO ICL™ for vision correction. The company designs, manufactures and sells implantable lenses for the eye and related delivery systems, with ICL products forming the core of its revenue base.
Recurring updates cover quarterly and annual results, preliminary sales, strategic-plan progress, market trends in China, the Americas and other international markets, regulatory indication changes, clinical evidence for EVO ICL, product adoption milestones, board and executive transitions, and shareholder voting or governance matters.
STAAR Surgical (NASDAQ:STAA) announced that independent analysts and proxy advisor ISS view the amended Alcon (SIX/NYSE:ALC) merger as providing value to STAAR stockholders. Under the revised agreement dated December 9, 2025, STAAR stockholders would receive $30.75 per share in cash, equal to a 74% premium to STAAR's 90-day VWAP as of August 4, 2025 and a 66% premium to the August 4 closing price.
Analysts cited a ~$1.6bn all-in valuation (~4.5x forward EV/Sales using blended 2026–2027 estimates of $271m and $300m) and noted limited competing bids after the go-shop. ISS updated its report to recommend shareholders vote FOR. A virtual Special Meeting is set for December 19, 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Broadwood Partners (owner of 30.2% of STAAR Surgical, NASDAQ: STAA) on Dec 9, 2025 responded to Alcon Inc.'s (NYSE: ALC) amended acquisition terms, urging shareholders to vote AGAINST the proposed sale. Broadwood says the board ran a flawed process, delayed votes three times, rejected other bidders, added a limited go‑shop, and accepted only a $150 million price bump (to $30.75 per share from $28). Broadwood highlights a $24 million CEO payout under original terms and asserts STAAR is worth substantially more as an independent company if management projections are met.
Alcon (SIX/NYSE: ALC) announced an amended merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $30.75 per share in cash, increasing the offer by roughly $150 million of equity value. The transaction represents an approximate $1.6 billion total equity value, a 74% premium to STAAR’s 90-day VWAP and a 66% premium to STAAR’s August 4, 2025 closing price.
Alcon said it will finance the deal with short- and long-term credit facilities, expects the merger to be accretive to earnings in year two, and anticipates closing in early 2026, subject to regulatory and STAAR stockholder approvals. STAAR stockholders are urged to vote ahead of a December 19, 2025 meeting.
Summary not available.
Summary not available.
Summary not available.